Andrew Joseph

London

Reporter at STAT

Reporter at @statnews, covering health and medicine out of Europe. Past: SA Express-News, SF Chronicle. [email protected]

Featured in: Favicon

statnews.com Favicon

businessinsider.com Favicon

foxnews.com Favicon

huffpost.com Favicon

scribd.com Favicon

cnbc.com

pbs.org

boston.com Favicon

mdpi.com

news.com.au + 110 more

Articles

U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service

5 days ago | statnews.com | Andrew Joseph

LONDON — A U.K. health agency reiterated on Thursday that the limited benefits of a pair of new Alzheimer’s drugs do not justify their high prices, meaning the medicines won’t be made available through the National Health Service.
Sarepta reports second patient death after treatment with Duchenne gene therapy

1 week ago | statnews.com | Andrew Joseph

Sarepta Therapeutics said Sunday that it was halting shipments of its Duchenne muscular dystrophy gene therapy for patients who can no longer walk, following the death of a second person who received the treatment. Sarepta disclosed the first patient death — a 16-year-old boy — in March. Both occurred from acute liver failure, a side effect that has been seen with other gene therapies.
Sarepta reports second patient death after treatment with Duchenne gene therapy

1 week ago | flipboard.com | Andrew Joseph

2 days agoIn this week’s edition of The Prototype, we look at a big space stock IPO, Korea’s plan to dominate the world of robots, building electric motors without metal and more. You can sign up to get The Prototype in your inbox here. Space company Voyager Technologies brought in nearly $383 million in its …
BioNTech to buy CureVac in $1.25 billion deal, saying it will bolster cancer work

1 week ago | statnews.com | Andrew Joseph

BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in an all-stock transaction. As part of the deal, CureVac investors will get $5.46 in BioNTech shares for each CureVac share, amounting to a 55% premium on CureVac’s average share price from the past three months. CureVac shareholders will own between 4% and 6% of BioNTech. Both companies are based in Germany.
A closer look at the new members of the CDC vaccine advisory panel

1 week ago | statnews.com | Lizzy Lawrence |Matthew Herper |Isabella Cueto |Elizabeth Cooney |Andrew Joseph |Daniel Payne | +1 more

For more than a half-century, the Centers for Disease Control and Prevention have relied on outside experts to guide the agency’s recommendations on how vaccines should be used to prevent the spread of infectious disease. That task will now fall to a panel that includes several individuals who’ve either been openly critical of vaccines or who have scant infectious disease expertise.
Sanofi to buy Blueprint Medicines in deal worth more than $9 billion

3 weeks ago | bostonglobe.com | Andrew Joseph

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.
Sanofi to buy Blueprint Medicines in deal worth more than $9 billion

3 weeks ago | statnews.com | Andrew Joseph

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company. Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.
Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials

3 weeks ago | statnews.com | Andrew Joseph

An experimental COPD medicine from Sanofi and Regeneron Pharmaceuticals produced mixed results in a pair of studies, the companies said Friday, sending both firms’ shares down in early and pre-market trading. The drug, called itepekimab, carries high hopes as the companies look for the next medicine that can produce the successes seen with Dupixent, their jointly marketed blockbuster. Dupixent is approved for a number of immune-mediated diseases, and picked up the green light for COPD last year.
What is WHO without the U.S.? Health officials wrestle with future at annual meeting

1 month ago | statnews.com | Andrew Joseph

GENEVA — The U.S. has been accused of acting as an 800-pound gorilla on the global stage. Its absence this week from the World Health Organization’s annual meeting of its members cast it as an equally sized specter. WHO officials and delegates from different countries and aid groups spoke repeatedly of the disruption and crisis in international funding.
With U.S. absent, WHO adopts pandemic treaty aimed at improving vaccine access

1 month ago | statnews.com | Andrew Joseph

GENEVA — World Health Organization members on Tuesday adopted a treaty aimed at preparing for and responding to future pandemics, what countries say is both a tangible example of how they’re learning the lessons of Covid-19 and a marker for the continued importance of international collaboration. Health officials hailed the treaty, a goal of which is to enable the more equitable distribution of vaccines and treatments, as a historic milestone.